Diversified Trust Co Lowers Position in DexCom, Inc. (NASDAQ:DXCM)

Diversified Trust Co reduced its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 53.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,357 shares of the medical device company's stock after selling 20,175 shares during the quarter. Diversified Trust Co's holdings in DexCom were worth $1,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of DXCM. Versant Capital Management Inc purchased a new stake in DexCom in the 4th quarter worth $25,000. Sachetta LLC boosted its stake in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after acquiring an additional 171 shares during the period. Riverview Trust Co grew its position in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new stake in DexCom during the 3rd quarter valued at approximately $57,000. Finally, Covestor Ltd lifted its holdings in DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company's stock worth $64,000 after purchasing an additional 335 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Up 0.9 %

Shares of DXCM traded up $0.74 during mid-day trading on Thursday, reaching $80.09. 2,423,035 shares of the company's stock traded hands, compared to its average volume of 2,644,387. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock's 50-day moving average is $76.78 and its two-hundred day moving average is $79.52. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a market cap of $31.28 billion, a P/E ratio of 47.96, a P/E/G ratio of 2.46 and a beta of 1.12.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DXCM shares. Citigroup lifted their price objective on shares of DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Leerink Partners dropped their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Wells Fargo & Company lifted their target price on DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Sanford C. Bernstein raised their price target on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Finally, Oppenheimer decreased their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $98.00.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.30% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.